Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Leukemia stem cells (LSCs) drive the initiation and perpetuation of AML, are quantifiably associated with worse clinical outcomes, and often persist after conventional chemotherapy resulting in relapse [1] [2] [3] [4] [5] . In this report, we show that treatment of older patients with AML with the B cell lymphoma 2 (BCL-2) inhibitor venetoclax in combination with azacitidine results in deep and durable remissions and is superior to conventional treatments. We hypothesized that these promising clinical results were due to targeting LSCs. Analysis of LSCs from patients undergoing treatment with venetoclax + azacitidine showed disruption of the tricarboxylic acid (TCA) cycle manifested by decreased α -ketoglutarate and increased succinate levels, suggesting inhibition of electron transport chain complex II. In vitro modeling confirmed inhibition of complex II via reduced glutathionylation of succinate dehydrogenase. These metabolic perturbations suppress oxidative phosphorylation (OXPHOS), which efficiently and selectively targets LSCs. Our findings show for the first time that a therapeutic intervention can eradicate LSCs in patients with AML by disrupting the metabolic machinery driving energy metabolism, resulting in promising clinical activity in a patient population with historically poor outcomes.
B
CL-2 is an anti-apoptotic member of the BCL-2 family of proteins 6 ; it is overexpressed in LSCs, and preclinical studies suggest targeting BCL-2 can result in the preferential elimination of this population [7] [8] [9] [10] . Our previous work demonstrated LSCs to be uniquely dependent on OXPHOS; BCL-2 inhibition impedes OXPHOS 7 , suggesting BCL-2 inhibition may target LSCs in patients with AML. Venetoclax is an orally bioavailable BH3 mimetic protein that selectively inhibits BCL-2 11 . Preclinical testing showed activity in AML, as did a single-agent clinical trial in relapsed or refractory patients 12, 13 . This prompted a dose escalation study of venetoclax with a hypomethylator backbone of azacitidine or decitabine for newly diagnosed older patients with AML (NCT02203773) 14 , which revealed it to be an active, well-tolerated therapy with an overall response rate of 78%, median response duration of 11 months and overall survival (OS) of 15 months 14 . In the present study, we explored the LSC-directed mechanism of venetoclax + azacitidine in newly diagnosed older patients with AML using clinical outcomes and pre-/post-treatment samples from 33 patients from our institution enrolled on the clinical trial 14 . Baseline characteristics of our patients are summarized in Table 1 and Supplementary Table 1 . The overall response rate (complete remission (CR) + CR with incomplete hematological recovery (CRi) + partial response (PR) + morphologic leukemia free state (MLFS)) was 91% (30/33) . Twenty (61%) had a CR, eight (24%) had a CRi and one each had a PR and MLFS. Median time to response was 34.5 days , and 19 patients (58%) achieved their best response after the first cycle. Three had no response; one was refractory after two cycles, and two discontinued the study before the first week of treatment completed for personal reasons. This regimen was well tolerated; the toxicity profile was consistent with what has been previously reported 14 . Nine responders (30%) relapsed; three relapsed after discontinuing therapy for reasons unrelated to toxicity, 44-165 days after discontinuation. Six relapsed while on therapy, 168-420 days after first response. Median follow-up time was 580 days (95% CI 377, 713). Median response duration, progression-free survival (PFS) and OS have not been reached (Fig. 1a-c) .
We compared these outcomes with control patients treated at our institution. For the control population, 285 newly diagnosed patients with AML consecutively treated with any therapy besides venetoclax + azacitidine at our institution over a seven-year period were screened; we selected those > 59 years with intermediate to adverse cytogenetics (n = 88; Supplementary Table 2 ). The CR/CRi rate for controls was 51%, inferior compared with the 85% that achieved CR/CRi with venetoclax + azacitidine (z-score = − 3.102, P = 0.0019). In addition, the median OS for venetoclax + azacitidine was superior to controls (not reached versus 341.5 days, P = 0.0003, Fig. 1d ). See Supplementary Fig. 1 for additional analyses stratified by treatment and age.
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Prior to initiation of therapy, patient specimens were genotyped using the TruSight myeloid panel (Supplementary Table 4) to assess patient-specific mutations. Of patients who completed more than one week of therapy, 3 of 4 with FLT-3 internal tandem duplications, 2 of 2 with TP53 mutations and 5 of 5 with monosomal karyotypes experienced a CR/CRi. BH3 profiling of seven patients showed no correlation between response and degree of BCL-2 priming (Supplementary Table 2) , and univariate logistic regression did not reveal any other relevant variables as response predictors (Supplementary Table 3 ). Isocitrate dehydrogenase (IDH) isoform 1 or 2 predicted longer responses (hazard ratio = 0.119 [0.015, 0.923], P = 0.042), while PTPN11 and other RAS pathway mutations predicted shorter responses (hazard ratio = 10.22 [2.36, 43 .48]; P = 0.0019).
Measurable residual disease (MRD) was evaluated using droplet digital PCR (ddPCR) in 22 patients for whom detectable mutations were available ( Fig. 1e ; see Supplementary Table 3 for baseline mutational profiles). Of the nine patients who relapsed, seven were analyzable for MRD by ddPCR; 0/7 had achieved MRD negativity. Eleven patients are in sustained remission with MRD positivity. Four patients achieved MRD negativity, defined as a lack of detectable evidence of all analyzed mutations; 0 of 4 have relapsed with a median follow-up time of 823 days (623-1,093), and two (patients 1 and 2), who opted to come off all treatment after achieving a remission after 1 and 3 cycles, remain MRD negative with no clinical signs of disease after 983 and 1,093 days, respectively.
We examined peripheral blood from patients with circulating disease to investigate cellular events that accompanied responses to venetoclax + azacitidine. We noted rapid decreases in peripheral blood blasts in patients with circulating disease, with significant reduction in as little as 24 h and complete eradication in all patients within six days of treatment (Fig. 2a and Supplementary  Table 5 ). Selected pre-and post-treatment patient samples were then interrogated using mass cytometry. As shown in Fig. 2b and Supplementary Table 4a, the effects of treatment were highly selective for the phenotypically defined AML blast cell population, with a dramatic and rapid reduction in tumor burden, consistent with the clinical experience with this regimen. Importantly, examination of phenotypically defined LSCs (CD34 + , CD38
+ ) also demonstrated rapid eradication (Fig. 2c) . By comparison, analysis of patients undergoing treatment with standard induction chemotherapy showed strikingly different results, with no significant reduction in blasts during the first four days of treatment; this was observed regardless of whether patients ultimately responded to this therapy (Supplementary Table 4b ). The venetoclax + azacitidine regimen also showed high specificity for malignant versus nonmalignant cells. As shown in Supplementary Table 4c, no reduction  in normal hematopoietic lineages CD3 + , CD7 + , or CD19 + subpopulations were evident after four days of therapy with this regimen.
To further investigate the molecular characteristics of cells targeted during the initial stages of treatment, we performed single-cell RNA-seq studies at baseline and after two and four days of therapy (Fig. 2d,e) . In this analysis, various cell populations were identified by expression of lineage-specific transcripts (see Supplementary  Fig. 5 for annotation) . As observed for the immunophenotypic analysis in Fig. 2 , we saw no changes in normal hematopoietic cells, while cells identified as blasts were rapidly depleted. Gene set enrichment analysis comparing global expression changes between leukemic and normal cells pre-and post-treatment demonstrated the population eradicated by venetoclax + azacitidine strongly expressed molecular signatures identified in primary human LSCs (Fig. 2f ) 15, 16 . These data, combined with the phenotypic findings ( Fig. 2c) , suggest targeting of primitive AML populations is preferentially achieved with venetoclax + azacitidine.
We have previously reported that low reactive oxygen species (ROS-low) AML cells are highly enriched in functionally defined LSCs 7, 17 and because ROS labeling is based on metabolic properties and not immunophenotypic markers, this approach circumvents the antigenic heterogeneity commonly observed in primary human AML specimens 18, 19 (see Supplementary Fig. 6 for ROS-low isolation method). Notably, RNA-seq analysis of ROS-low specimens isolated 6 h after the initiation of treatment with venetoclax + azacitidine showed that pathways related to OXPHOS were strongly downregulated ( Supplementary Fig. 7 ), a significant finding as it is known that OXPHOS is a critical pathway for LSC maintenance and survival 7 .
Preclinical studies have previously shown that BCL-2 inhibition decreases OXPHOS, leading to death of LSCs but not normal hematopoietic stem cells, as normal stem cells compensate for reduced OXPHOS through increased glycolysis 7 . Based on our clinical findings of frequent, deep and durable responses with venetoclax + azacitidine, we hypothesized that this regimen targets LSCs in patients by decreasing OXPHOS. We tested this hypothesis by performing metabolomic analyses on tumor specimens obtained from patients pre-and 24 h post-treatment with venetoclax + azacitidine. Analysis of ROS-low cells showed that patient 7 had a significant decrease in basal OXPHOS post-treatment (Fig. 3a) , and that patient 9 had a significant decrease in OXPHOS spare capacity post-treatment ( Fig. 3b and Supplementary Fig. 8a ). Importantly, decreased OXPHOS observed on treatment with venetoclax + azacitidine was not observed in patients treated with standard induction chemotherapy (7 + 3) (Supplementary Fig. 8b ). Furthermore, two of three patients receiving azacitidine alone did not have alterations in OXPHOS levels on azacitidine treatment ( Supplementary Fig. 8c ).
Next, we confirmed these results in vitro by treating LSCs isolated from patients for 4 h with venetoclax + azacitidine. We found a reduction in OXPHOS in 4 of 4 of the samples tested from patients with AML ( Fig. 3c and Supplementary Table 6 ). Notably, venetoclax + azacitidine did not significantly reduce OXPHOS in ROS-high AML blasts ( Supplementary Fig. 8d ). The expected consequence of decreased OXPHOS in LSCs is reduced ATP levels, which was indeed detected in treated specimens (Fig. 3d) . Overall, these data are consistent with our preclinical findings and demonstrate venetoclax + azacitidine decreases OXPHOS and energy production in patients with AML.
To determine how venetoclax + azacitidine decreases OXPHOS we measured changes in metabolite abundance pre-and 24 h posttreatment. Of particular interest were TCA cycle intermediates, as these metabolites supply substrate for OXPHOS directly through ETC complex II activity. We also observed a significant decrease in glutathione levels in 3 of 3 patients post-treatment (Fig. 3f) , an event that correlates with increased cellular ROS (Fig. 3g) . Interestingly, patients receiving '7 + 3' also had increased levels of ROS ( Supplementary Fig. 8e ) suggesting that elevated ROS alone is not sufficient to target LSCs in patients. Glutathione has multiple crucial cellular functions, including regulation of the activity of succinate dehydrogenase A (SDHA) 20 , a component of ETC complex II. Glutathionylation, a post-translation modification, has been shown to increase ETC complex II activity 20 . Therefore, we hypothesized that venetoclax + azacitidine results in decreased Oxygen consumption rate as a measure of OXPHOS was quantified pre-and 24 h post-treatment with venetoclax + azacitidine in the leukemia cells isolated from a patient with AML, revealing a significant reduction in OXPHOS levels. n = 3-5, technical replicates. Significance was measured by unpaired two-tailed Student's t-test. b, Using FCCP to uncouple the electron transport chain and maximize oxidative phosphorylation, the oxygen consumption rate was measured in the leukemia cells of one patient before and 24 h after treatment, revealing a significant decrease in the ability of the post-treatment leukemia cells to maximize oxygen consumption. n = 3-4 technical replicates. Significance was measured by unpaired two-tailed Student's t-test. c, Oxygen consumption levels were measured in ROS-low LSCs isolated from four primary AML specimens, A, B, C, and D, treated with 500 nM venetoclax + 2.5 µ m azacitidine in vitro for 4 h. n = 4 (biological)/n = 5 (technical) replicates. Significance was measured by paired two-tailed Student's t-test. d, ATP production was measured in ROS-low LSCs isolated from three primary AML specimens, A, B, and C, treated with 500 nM venetoclax + 2.5 µ m azacitidine in vitro for 4 h. n = 3 (biological)/n = 5 (technical) replicates. Significance was measured by paired two-tailed Student's t-test. e-g, Three patients with circulating blasts sampled from the peripheral blood at baseline and 24 h after treatment with venetoclax + azacitidine show evidence of decreased electron transport chain complex II activity. e, Levels of TCA cycle intermediates, α -ketoglutarate, succinate, citrate, fumarate, malate, oxaloacetate in patients pre-and 24 h post-venetoclax + azacitidine treatment. n = 3 (biological)/n = 2-5 (technical) replicates. Significance was measured by unpaired two-tailed Student's t-test. f, Levels of glutathione in patients pre-and 24 h post-venetoclax + azacitidine treatment. n = 3 (biological)/n = 2-5 (technical) replicates. Significance was measured by unpaired two-tailed Student's t-test. g, Cellular ROS in leukemia cells from patients pre-(red shaded histogram) and 24 h post-(blue shaded histogram) venetoclax + azacitidine treatment (as determined by labeling with CellROX). ROS was measured in each individual patient once. Bars represent the mean of the replicates and error bars represent standard deviation for each bar graph. Statistical tests were performed on technical replicates only when assay was measuring metabolic responses of individual patients on therapy. NS, not significant; AU, arbitrary units. 
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To test this hypothesis, we directly measured ETC complex II activity and SDHA glutathionylation in primary AML specimens upon venetoclax + azacitidine treatment in vitro. In addition, we assessed the importance of glutathione in ETC complex II activity, as well as OXPHOS. First, we confirmed our in vivo observation that venetoclax + azacitidine decreases glutathione levels in vitro (Fig. 4a) . Next, we showed decreased glutathionylation of SDHA after treatment with venetoclax + azacitidine (Fig. 4b) , and then showed that this correlated with reduced ETC complex II activity (Fig. 4c) . Furthermore, pretreatment of leukemic cells with cellpermeable glutathione increased intracellular glutathione even in the presence of venetoclax + azacitidine (Fig. 4d) . Cell-permeable glutathione also induced a partial rescue of ETC complex II activity on venetoclax + azacitidine treatment (Fig. 4c) . We next measured succinate levels and observed that on treatment with venetoclax + azacitidine, intracellular succinate was elevated (Fig. 4e) , consistent with a loss of glutathione. Pretreatment with cell-permeable glutathione completely restored succinate to normal levels demonstrating a reciprocal relationship between glutathione and succinate in cells treated with venetoclax + azacitidine. These data suggest decreased glutathione levels from venetoclax + azacitidine are at least partially responsible for reduced ETC complex II activity.
To determine the impact of glutathione reduction on OXPHOS, we measured OXPHOS in ROS-low LSCs after pretreatment with cell-permeable glutathione followed by venetoclax + azacitidine. As shown in Fig. 4c , venetoclax + azacitidine decreased OXPHOS in LSCs. However, pretreatment with cell-permeable glutathione partially rescued OXPHOS levels on venetoclax + azacitidine treatment (Fig. 4f) . Furthermore, pretreatment with cell-permeable glutathione partially rescued the reduction in ATP levels after venetoclax + azacitidine treatment in LSCs (Fig. 4g) . Finally, we determined the functional role of decreased glutathione on LSC viability by showing that cell-permeable glutathione pretreatment partially rescued cell viability on venetoclax + azacitidine treatment (Fig. 4h) . Interestingly, the decreases in SDHA glutathionylation, ETC complex II activity, OXPHOS, and ATP levels only occurred on treatment with both venetoclax + azacitidine, and not with either agent individually ( Supplementary Fig. 9a-f) . Furthermore, venetoclax + azacitidine resulted in synergistic cell killing in five of six primary AML specimens tested ( Supplementary Fig. 9g ) 21, 22 . However, venetoclax or azacitidine alone can increase ROS levels and the ROS levels induced by venetoclax + azacitidine are not significantly higher than that seen with the individual agents ( Supplementary  Fig. 9h ). Overall, these findings support the hypothesis that the combination of venetoclax + azacitidine decreases OXPHOS via disruption of ETC complex II in a glutathione-dependent fashion, resulting in the selective targeting of the LSC population.
To date, treatment options for older patients with AML have been limited. Single-agent azacitidine in untreated older patients results in a CR/CRi rate of 28% with a response duration of 10 months 23 . Venetoclax + azacitidine showed greater activity with more durable responses; our single-institution data were comparable with the clinical results of the larger study in which we participated 14 , and, when compared with a single institution internal control population, were superior with respect to response rates and OS to all other therapies.
Durability is related to the depth of response, which can be measured by MRD 24 . Using ddPCR we showed MRD negativity can be achieved with a non-intensive regimen and correlates with sustained remissions. Larger numbers and longer follow-up will be needed to fully recognize the clinical significance of responses of this depth, and to determine baseline characteristics that may predict MRD negative responses.
We previously hypothesized that an effective LSC-directed therapy should result in deep remissions and have curative potential 25, 26 ; two patients described here have achieved sustained MRD negative responses off all therapy for nearly three years, and others who remain on therapy have achieved similar response depth and durability, suggesting this regimen may be curative in some settings. However, while nearly all patients responded, some progressed. Consistent with prior preclinical and clinical observations 10,13 , we report patients with IDH mutations had longer remission durations. Additionally, we report here that RAS pathway mutations predicted shorter remissions, which may help elucidate mechanisms of resistance to this regimen. We previously predicted that LSC-directed treatment may be effective irrespective of traditional biological risk factors 25, 26 . This concept is supported by the results of the present study, in which no traditional adverse risk disease features predicted a lack of response to the venetoclax + azacitidine regimen. Lastly, LSC-directed therapies may be expected to be more effective in the up-front treatment setting, based on the finding that LSCs are substantially fewer and more homogeneous prior to relapse 19 . Perturbing the metabolic environment to target cancer has been an appealing strategy since it was first recognized that some cancer cells favor glycolysis over oxidation, known as the Warburg effect 27 . It has recently been reported in preclinical models that a 'reverse Warburg' effect, involving reliance on OXPHOS for metabolism, is observed in several cancer stem cell subtypes, including LSCs 7, 28, 29 .
Here we show that disruption of energy metabolism can be a therapeutic strategy for AML. Specifically, reduction in OXPHOS resulting in targeting of LSCs was achieved through reduced ETC complex II activity and induction of ROS within 24 h of treatment with venetoclax + azacitidine. In vitro modeling suggests that decreased glutathione, which reduces ETC complex II activity, is at least partially responsible for the reduced OXPHOS and LSC targeting. Importantly, the combination of venetoclax + azacitidine was needed to decrease glutathione levels, suggesting future venetoclax-containing treatment regimens should continue to include azacitidine. We note that contrary to our previous in vitro studies 7 , the experiments presented in the current study show that venetoclax alone is not sufficient to mediate OXPHOS inhibition in vivo. Rather, the combination of venetoclax + azacitidine is necessary to downregulate OXPHOS ( Supplementary Fig. 9e ), which perhaps at least partially explains the efficacy of the drug combination in patients. These findings complement and extend several recent preclinical studies that demonstrate an important role for mitochondrial metabolism in LSC survival 7, 10, [30] [31] [32] . Although we believe the depth and durability of responses seen here are due to selective LSC targeting, the ability of this regimen to eradicate bulk tumor is impressive, with rapid reduction of peripheral blasts and a high remission rate observed after the first cycle of therapy. This would be an unexpected finding for a pure LSC-directed mechanism and is probably due to the well-described promotion of apoptosis via targeting BCL-2 12, 33 . While our de novo specimens did not consistently show a high level of BH3 priming, we speculate that azacitidine may induce a physiological state that makes AML cells more susceptible to BCL-2 inhibition 34, 35 .
In conclusion, venetoclax + azacitidine is highly active in older, previously untreated patients with AML; responses are deep and durable, and outcomes are superior compared with historical controls. Mechanistic experiments done with specimens obtained from patients early during the course of therapy indicate that the LSC compartment can be effectively eradicated by targeting LSC-specific metabolic properties.
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Methods
Trial design. The dose escalation and expansion clinical trial (NCT02203773) was conducted in compliance with the Declaration of Helsinki and was approved by all relevant institutional review boards; all patients gave written informed consent. The regimen, described in detail elsewhere, was comprised of azacitidine 75 mg m −2 on days 1-7 of each 28-day cycle, with concomitant daily venetoclax taken orally for the entire cycle; cycles could be repeated indefinitely in the absence of toxicity or disease progression 14 . During dose escalation patients were assigned to receive 400, 800, or 1,200 mg venetoclax; during dose expansion, all patients received 400 mg. Eligible patients were ≥ 60 with newly diagnosed AML without favorable cytogenetics 36 , had received no prior treatment, and had adequate organ function. Response assessments were made according to the International Working Group for AML 37 . Patients treated at our institution who achieved a MLFS or CRi had their response upgraded to a CRi or CR if a break in therapy and/or the use of growth factor support allowed for count recovery within 14 days of the bone marrow biopsy, without any other intervening treatment.
Clinical statistics. Median follow-up was calculated using the reverse KaplanMeier method. OS and PFS were calculated from the date of study entry to the date of death from any cause or the date of relapse or death. Response duration was calculated from the date of initial response to relapse. Living patients who had not progressed on or before 28 February 2018 were censored. Median OS was calculated using Kaplan-Meier product limit estimates. Univariate logistic regression analysis was used to assess the effects of covariates on response status; P values are two-sided, and a P value threshold of 0.05 was used to indicate significance. Response rates between venetoclax + azacitidine and control cohorts were compared using the z-score in a difference in proportions test, and OS between these groups was compared using a Mantel-Cox logrank test. Analyses were performed using SAS version 9.4 (SAS Institute).
Next generation mutational sequencing. Mutational analysis using a targeted sequencing panel of 49 AML-associated genes was performed on diagnostic bone marrow from all but one patient (Supplementary Table 3) ; in most cases, germline DNA extracted from fingernails was analyzed to ensure the somatic origin of detected mutations. Sequencing was done using the Raindance Myeloid Thunderbolt panel per the standard protocol. Briefly, genomic DNA extracted from the specimens was used for multiplex PCR amplification of 548 amplicons that target mutation hot spots in 49 genes recurrently mutated in AML. Next generation sequencing was performed on Illumina MiSeq and analyzed with SoftGenetics NextGENe data analysis software. The UCSC hg19 and GRCh 37 reference genomes were used as the reference sequence. As many diseaseassociated mutations as possible from the maximum number of patients were selected for subsequent MRD analysis using ddPCR (Supplementary Table 6 ) and quantified at various timepoints during therapy. The limit of detection was 0.02-0.05%.
Human specimens. AML specimens were obtained from bone marrow and peripheral blood of patients who gave informed consent for tissue banking at the University of Colorado (COMIRB no. 12-0173 and 06-0720). Total mononuclear cells were isolated from specimens by standard Ficoll procedures as previously described 19 (GE Healthcare).
Cell culture and media. Primary cells were cultured as described previously by Pei et al 38 . Primary human AML cells were resuspended at about 100-200 × 10 6 cells per ml in freezing media composed of 50% FBS (GE Healthcare), 10% DMSO (Sigma), and 40% IMDM media (Gibco) and then cryopreserved in liquid nitrogen. Cells were thawed in 37 °C water bath, washed twice in thawing media composed of IMDM (Gibco), 2.5% FBS (GE Healthcare), and 10 μ g ml -1 DNase (Sigma). Cells were cultured in serum-free media (SFM) in 37 °C, 5% CO 2 incubator. SFM is composed of IMDM (Gibco), 20% BIT 9500 (STEMCELL Technologies), 10 μ g ml −1 low-density lipoprotein (Millipore), 55 μ M 2-mercaptoethanol (Gibco), and 1% Pen/Strep (Gibco). Complete SFM were made by supplementing the normal SFM with FLT-3, IL-3, and SCF cytokines (PeproTech), each at 10 ng ml Droplet digital PCR methods. Bone marrow or peripheral blood samples were either lysed whole or Ficoll separated and the mononuclear cell population lysed for DNA. Genomic DNA extraction was performed using the QIAamp DNA Mini kit (Qiagen), and quantity and purity were measured via NanoDrop. DdPCR assays for AML-associated mutations were designed either by our laboratory or obtained pre-designed from RainDance Technologies (Supplementary Table 7 ). These assays utilize common forward and reverse primers that span a single nucleotide polymorphism of interest, as well as competitive TaqMan probes for wild-type and mutant alleles (labeled with VIC or FAM fluorophores, respectively). All assays were validated via quantitative PCR as well as ddPCR to ensure optimal annealing temperatures and minimal false-positive reads, using no template controls and known wild-type DNA samples for reference. DNA (100 ng) was added to a PCR master mix containing gene-specific primers and probes, droplet stabilizer, and ABI TaqMan Genotyping Master Mix (4371355). PCR samples were loaded onto a RainDance Source chip, which was then inserted into the RainDance Source instrument to generate picoliter-size droplets containing individual molecules of DNA template. Dropletized samples were subjected to standard PCR using assay-optimized annealing temperatures. PCR-amplified samples were then placed into a droplet reader (RainDance Sense instrument) which counts individual droplets as 'negative' , 'FAM-positive' , or 'VIC-positive' . Data were generated as .fcs files, which were then analyzed with RainDrop Analyst II software. Variant allele frequencies (VAFs) are expressed as the percentage of mutant (FAM)-positive droplets relative to the total number of positive droplets (FAM + VIC). In some cases, VAFs determined via the RainDance ddPCR platform were confirmed using an alternative ddPCR platform, the Bio-Rad QX200.
Mass cytometry. These samples were processed and stained as described in Amir et al. 39 . Briefly, frozen aliquots of cells were thawed in 98% IMDM + 2% FBS + DNase I. Thawed cell pellets were immediately resuspended in PBS containing 5 µ M Cell-ID Cisplatin (Fluidigm) and incubated for 5 min at room temperature. Cells were washed one time with cell-staining buffer and fixed using 2% formaldehyde for 10 min at room temperature. Fixed cells were washed with cell-staining media (low barium PBS + 0.5% bovine serum albumin + 0.02% sodium azide) and incubated for 30 min at room temperature in surface epitope metal-conjugated antibodies (see Supplementary Table 8 for panel of reagents). Surface-stained cells were washed twice and resuspended in cold methanol for 30 min at 4 °C. Methanol-permeabilized cells were washed one time and resuspended in intracellular epitope metal-conjugated antibody mix for 1 h at room temperature. Stained cells were washed once before incubation in 0.5 µ M Cell-ID Intercalator-Ir (Fluidigm). Fixed and stained cells were washed two times in cell-staining media and resuspended at 2.5-5 × 10 5 per ml in water before being run on a CyTOF instrument. Data were analyzed utilizing the viSNE algorithm, which was used to visualize and interpret data 39 .
Single-cell RNA-seq. Single-cell RNA sequencing data was initially processed by the Cell Ranger pipeline (v2.0.1) from 10x Genomics. The generated count matrices were then analyzed using the Seurat package (v2.2.1) in R. Read counts were normalized to library size, scaled by 10,000, log-transformed, and filtered based on the following criteria: cells with less than 250 genes detected or with a proportion of unique molecular identifiers mapped to mitochondrial genes over 0.15 were excluded from analysis; genes detected in less than 5 cells were also excluded. Cell-to-cell variation in gene expression driven by the number of detected molecules and mitochondrial gene expression was regressed out using linear regression. Dimensionality reduction was performed with principal component analysis followed by t-SNE projection and graph-based clustering using the first 15 principal components. Data are available in GEO (accession number: GSE116481).
RNA-seq.
The TruSeq RNA Sample Preparation Kit V2 (Illumina) was used for next generation sequencing library construction per the manufacturer's protocols. Amplicons were ∼ 200-500 base pairs in size. The amplified libraries were hybridized to the Illumina single end flow cell and amplified using the cBot (Illumina). Single end reads of 100 nucleotides were generated for each sample and aligned to the organism-specific reference genome. Raw reads generated from the Illumina HiSeq2500 sequencer were demultiplexed using configurebcl2fastq.pl version 1.8. Global metabolomics. Metabolomic analyses were performed via ultra-high pressure liquid chromatography-mass spectrometry (UHPLC-MS Vanquish and Q Exactive, Thermo Fisher) as previously reported 40 , and quantification of compounds of interest was performed against 13 C or D stable isotope labeled standards (Sigma-Aldrich and Cambridge Isotopes), as described 40 . A detailed description of this method is included in the supplementary materials.
Cell sorting. Primary AML specimens were thawed, stained with CD45 (BD, 571875) to identify the blast population, CD19 (BD, 555413) and CD3 (BD, 557749) to exclude the lymphocyte populations, DAPI (EMD Millipore, 278298), and CellROX deep red (Thermo Fisher, C10422), and sorted using a BD FACSARIA. ROS-low LSCs were identified as the cells with the 20% lowest ROS levels and the ROS-high blasts were identified as the cells with the highest 20% ROS levels, as previously described 17 .
Viability assays. Patient samples were sorted and cultured without indicated metabolites or drugs for 24 to 72 h. Viability was assessed by trypan blue (Gibco, 15250-071) staining and manual cell counting.
Seahorse assays. Extracellular flux assay kits XF24 (Agilent Technologies, 100850-001) or XF96 (Agilent Technologies, 102417-100) were used to measure oxygen Articles Nature MediciNe consumption and glycolytic flux. ROS-low LSCs or ROS-high blasts were sorted, drug treated for 4 h, or directly plated in an XF24 or XF96 cell culture microplate. Oxygen consumption and glycolytic flux were measured according to the manufacturer's protocol and as previously described 17 . Briefly, five replicate wells of 5 × 10 5 ROS-low LSCs, ROS-high blasts, or total AML blasts per well were seeded in a Cell-Tak (Corning, 324240) coated 24-well XF24 plate. At 30 min prior to analysis, the medium was replaced with Seahorse XF media (Agilent Technologies, 102353-100) and the plate was incubated at 37 °C. Analyses were performed both at basal conditions and after injection of 5 μ g ml −1 oligomycin (Sigma-Aldrich, 871744), 2 μ M FCCP (Sigma-Aldrich, C2920), 5 μ M antimycin A (Sigma-Aldrich, A8774), and 5 μ M rotenone (Sigma-Aldrich, R8875).
Immunoprecipitation and immunoblotting. Total cell lysates from venetoclax with azacitidine-treated cells were precleared with protein A/G magnetic beads (Thermo Fisher Scientific) at room temperature for 1 h. After preclearing, cell lysates were incubated with SDHA antibody (Cell Signaling) overnight at 4 o C. Protein-antibody complexes were then bound to protein A/G magnetic beads (Thermo Fisher Scientific) for 1 h at room temperature. After incubation, beads were sequentially washed 3 times with lysis buffer. Finally, the protein-antibodybead complexes were boiled for 10 min in non-reducing SDS-PAGE sample buffer to elute all pulldown products for western blot analysis. Lysates were loaded on a 10% polyacrylamide gel. Proteins were transferred to a polyvinylidene difluoride membrane using the mini trans-blot transfer system (Bio-Rad). To detect specific antigens, blots were probed with primary antibodies glutathione (Invitrogen), GAPDH (Santa Cruz), and SDHA (Cell Signaling) on a shaker at 4 °C, overnight, followed by 1 h of room temperature incubation with HRP-conjugated secondary antibodies (Santa Cruz). Chemoluminescence was recorded using the automated Gel Doc XR system (Bio-Rad).
Complex II activity assay. AML cells were treated with cysteinase or control inhibitors for 4 h, samples were prepared, and enzyme activity was quantified according to the manufacturer's protocol (Abcam, ab109908).
In vivo treatment of xenografts. Animal experiments were conducted in accordance with an approved protocol (IACUC no. 0308) at the University of Colorado. NSG-S mice were conditioned 24 h prior to transplant with 25 mg kg −1 busulfan via intraperitoneal injection. Bone marrow mononuclear cells (1.0 × 10 6 ) from patients with AML were transplanted via tail vein in a final volume of 0.1 ml PBS with 0.5% FBS. After 6 weeks, animals were separated to treatment and control groups (4 animals per group) and received either ABT-199 (100 mg kg 
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The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request. All patients were over 64 years old with AML that had not been previously treated and were deemed unfit for standard induction chemotherapy. Patients with poor performance status, major organ dysfunction or unable to take oral medications were excluded.
Recruitment
Patients were recruited based on referrals from colleagues or when they were diagnosed within our healthcare system. All potentially eligible patients were considered for this study.
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Methodology Sample preparation
Human primary bone marrow mononculear cells from frozen aliquots of cells were thawed in 98% IMDM + 2% FBS + DNase I. Thawed cell pellets were immediately re-suspended in PBS + 0.5% BSA before being stained at 4 degrees C for 20 minutes and washed twice with PBS+0.5% BSA. 
Gating strategy
For leukemia stem cell sorting by redox status the gating strategy was as follows: Initial gating done on FSC vs SSC plot to remove debris, subsequent gating done on this population included doublet removal using FSC-H vs FSC-A and a subsequent daughter gate of SSC-H vs SSC-A, the singlets were gated for viability through DAPI exclusion. The live cells were further gated for blasts utilzing a SSC vs human CD45 gate and a daughter gate of CD19 and CD3 negative cells. Lastly, the blast population was gated for the top and bottom 20% on a histogram plot of CellRox dye. The subsequent sorted cells were checked utilizing a post sort acquisition. A similiar strategy was utilized for the iBH3 profiling. The cells were stained utilzing a fixable live dead stain and the gating strategy was as follows: nitial gating done on FSC vs SSC plot to remove debris, subsequent gating done on this population included doublet removal using FSC-H vs FSC-A and a subsequent daughter gate of SSC-H vs SSC-A, the singlets were gated for viability through live dead dye exclusion. The live cells were subjected to a SSC vs CD45 plot for subsequent blast gating. The Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
